Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNAX accessory molecule-1 ligands (DNAM-1 ligands), primarily poliovirus receptor (PVR; CD155) and Nectin-2 (CD112), are cell surface glycoproteins belonging to the nectin and nectin-like families. They are expressed on endothelial cells at intercellular junctions, tumor cells, infected cells, and various normal cells including neuronal, epithelial, and fibroblastic cells. These ligands engage the activating receptor DNAM-1 (CD226) on NK cells, T cells, and monocytes to promote cytotoxicity, cytokine secretion, immune synapse formation, cell adhesion, and monocyte transendothelial migration during diapedesis. PVR (CD155) is the major ligand on endothelial cells and critical for NK-mediated tumor killing, while both ligands contribute to immune recognition of transformed or stressed cells. Expression is upregulated in tumorigenesis, viral infections, and inflammation.[1][2][3]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNAX accessory molecule 1 ligands (DNAM-1 ligands).